Written Question·Department of Health and Social Care·UIN 106958

Sodium Valproate: Health Education

Tabled: 20 January 2026

Answered: 27 January 2026

Question

Bob Blackman

To ask the Secretary of State for Health and Social Care, what assessment has been made of the MHRA’s effectiveness at communicating known risks of sodium valproate, particularly in pregnancy, prior to 2018.

Answer

Dr Zubir Ahmed

As with all medicines, the safety of valproate has been kept under continual review by the Medicines and Healthcare products Regulatory Agency (MHRA), ensuring the product information reflects what is known about valproate.The known risks of valproate are...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 106958) →